MacroGenics
MGNX
HK$9.97
Share price
0.00%
Change (1 day)
-68.63%
Change (1 year)
Categories
MacroGenics (MGNX) - Cash on Hand
Cash on Hand as of March 2025 : HK$1.20 Billion
According to MacroGenics's latest financial reports the company has HK$1.20 Billion in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
MacroGenics - Cash on Hand chart (from 2012 to 2025)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2024-12-31 | HK$1.56 B | -12.77% |
| 2023-12-31 | HK$1.79 B | 48.83% |
| 2022-12-31 | HK$1.20 B | -36.52% |
| 2021-12-31 | HK$1.89 B | -10.09% |
| 2020-12-31 | HK$2.11 B | 25.73% |
| 2019-12-31 | HK$1.68 B | -7.85% |
| 2018-12-31 | HK$1.82 B | -23.51% |
| 2017-12-31 | HK$2.38 B | 10.98% |
| 2016-12-31 | HK$2.14 B | -18.26% |
| 2015-12-31 | HK$2.62 B | 114.99% |
| 2014-12-31 | HK$1.22 B | 35.33% |
| 2013-12-31 | HK$0.90 B | 144.07% |
| 2012-12-31 | HK$0.37 B | -13.71% |
| 2011-12-31 | HK$0.42 B |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 Xencor XNCR | HK$3.68 B | 204.63% | 🇺🇸 USA |
 Pfizer PFE | HK$135.92 B | 11,133.87% | 🇺🇸 USA |
 Merck MRK | HK$72.43 B | 5,886.73% | 🇺🇸 USA |
 Gilead Sciences GILD | HK$62.21 B | 5,042.05% | 🇺🇸 USA |
 Amgen AMGN | HK$69.15 B | 5,615.55% | 🇺🇸 USA |
 Eli Lilly LLY | HK$25.28 B | 1,989.45% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | HK$92.48 B | 7,543.65% | 🇺🇸 USA |